Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Bags European Approval for Crysvita in TIO
August 22, 2022
- Xofluza Approved in US for Children Aged 5 and Older
August 22, 2022
- Lagevrio Joins NHI Price List, Normal Distribution to Start Once Ready
August 19, 2022
- Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
August 19, 2022
- Mochida to Roll Out Once-Daily Epadel on Sept. 12
August 19, 2022
- Forxiga Replaces Januvia as Japan’s No. 1 Diabetes Drug in April-June: IQVIA
August 18, 2022
- Incyte Japan Urges Reward for Innovation in Rare Diseases as Pemazyre Filed for Ultra Orphan Cancer
August 18, 2022
- Solasia, Nippon Kayaku to Launch PTCL Drug Darvias on Aug. 22
August 18, 2022
- Enhertu Smashes Primary Goal in PIII for HER2 Positive Metastatic Breast Cancer
August 18, 2022
- RaQualia Ties Up with Intracellular Antibody Upstart on Drug Discovery
August 17, 2022
- Japan’s First Long-Acting Injectable HIV Drug Holds Great Promise: ViiV Local Chief
August 17, 2022
- Edirol’s Tablet Forms Approved in Japan, Towa Responsible for Distribution
August 16, 2022
- US Arbitrator Rejects Seagen’s Claims against Daiichi Sankyo in ADC Feud
August 16, 2022
- UCB Files E Keppra for Children Aged One Month or Older
August 15, 2022
- Enhertu Gets Accelerated FDA Approval for 2nd Line NSCLC Use
August 15, 2022
- Chugai Gets Priority Review for PNH Med Crovalimab in China
August 12, 2022
- Sumitomo Pharma to Rev Up R&D for Regenerative Medicine, CNS towards Later 2030s
August 12, 2022
- Japan Ethical Drug Sales Inch Up 1.1% in June: Crecon
August 12, 2022
- AbbVie Seeks Crohn’s Disease Nod for Rinvoq in Japan
August 12, 2022
- Shionogi’s COVID Pill Shows In Vitro Antiviral Activity Against BA.2.75
August 12, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…